Dominari Holdings Inc.
Business Overview: Dominari Holdings Inc. (NASDAQ: DOMH)
Executive Summary
Dominari Holdings Inc. is a small-cap financial-services holding company built around Dominari Securities LLC, a wholly owned broker-dealer and registered investment adviser offering wealth management, investment banking, sales and trading, asset management, and insurance services. The company traces back to Spherix Incorporated, founded in 1967, and operated for years as the biotechnology firm AIkido Pharma, Inc. In June 2022, management formed Dominari Financial Inc. to pivot the company "away from biotechnology" and into fintech/financial services; the legacy drug-licensing pipeline is now being wound down through Dominari Labs, LLC.
The pivot was executed through acquisition: Dominari Financial bought Fieldpoint Private Securities, LLC in two tranches (20% for $2.0 million in October 2022, then the remaining 80% for $1.4 million in March 2023), renaming it Dominari Securities LLC. The firm has since layered on alternative-investment vehicles (Dominari Master SPV, American Ventures SPV) and an insurance joint venture, while remaining a genuinely small operation — 36 full-time employees as of year-end 2025.
Why it matters: DOMH is a case study in a shell-company pivot into regulated wealth management/investment banking, with an unusual amount of market attention driven by advisory-board ties to Donald Trump Jr. and Eric Trump, whose personal equity stakes have made the stock a retail-trading focal point disproportionate to its underlying revenue base.
1. Core Business Model & How They Work
Dominari does not manufacture a product — it monetizes client assets and transactions through its licensed broker-dealer/RIA subsidiary. Clients (high-net-worth individuals, executives, businesses) bring assets and deal flow to Dominari Securities, which earns transaction commissions, asset-based advisory fees (billed monthly in advance), investment-banking fees (earned on completed deals only), revenue-share/incentive fees from alternative-investment vehicles, and insurance-carrier compensation. Fees flow up through Dominari Financial Inc. to the public parent, subject to broker-dealer net-capital rules that can restrict how much cash moves upstream.
Clients (HNW individuals, executives, businesses, institutions)
|
v assets, trades, deal mandates
+-----------------------------------------------+
| Dominari Securities LLC (broker-dealer/RIA) |
| Wealth Mgmt | Inv. Banking | Sales & Trading |
| Asset Management | Insurance (via DFHS) |
+-----------------------------------------------+
|
v commissions, advisory fees, IB fees,
| revenue-share, insurance compensation
+-----------------------------------------------+
| Dominari Financial Inc. |
+-----------------------------------------------+
|
v (subject to regulatory capital limits)
+-----------------------------------------------+
| Dominari Holdings Inc. (NASDAQ: DOMH) |
+-----------------------------------------------+2. Business Segments
The company does not report distinct financial segments; it operates as one financial-services business delivered through several licensed entities.
Dominari Holdings Inc.
|
+-- Dominari Financial Inc. (holding co.)
| |
| +-- Dominari Securities LLC (broker-dealer / RIA)
| | - Wealth Management
| | - Investment Banking
| | - Sales & Trading
| | - Asset Management
| |
| +-- Dominari Manager LLC / Dominari IM LLC
| | -> advises Dominari Master SPV LLC (series funds, launched Mar. 2024)
| |
| +-- American Ventures Mgmt LLC / American Ventures IM LLC (90% owned)
| | -> advises American Ventures LLC / AV Master SPV (formed Jun. 2025)
| |
| +-- Dominari Financial Heritage Strategies LLC (DFHS)
| 50/50 JV w/ Heritage Strategies LLC; NY-licensed insurance business
|
+-- Dominari Labs, LLC (legacy biotech IP being wound down)- Wealth management & brokerage is the core, client-facing revenue engine.
- Alternative-investment SPVs (Dominari Master SPV, AV Master SPV) let the firm earn management/incentive fees on pooled vehicles without full balance-sheet risk.
- DFHS extends the client relationship into life insurance and annuities.
- Dominari Labs is a non-core wind-down of the old AIkido Pharma drug-licensing pipeline, not a going-forward growth driver.
3. Product Portfolio
| Service | Category | Purpose | Why It Matters |
|---|---|---|---|
| Full-service brokerage & wealth planning | Wealth Management | Manage individual/business client portfolios, retirement and trust services | Core recurring-fee relationship with HNW clients |
| Financial advisory & equity capital markets | Investment Banking | Advise on M&A and raise equity capital for issuers | High-margin, deal-contingent fee income |
| Debt capital markets (planned) | Investment Banking | Future debt-raising advisory for issuers | Signals intent to broaden IB fee base |
| Institutional equity & fixed-income trading, listed options, securities lending | Sales & Trading | Execute trades for institutional/HNW clients | Transaction-based revenue, market-making flow |
| Fee-based separately managed accounts & alternative investments | Asset Management | Discretionary/non-discretionary advisory accounts, SPV fund management | Stickier, asset-based fee revenue |
| Life insurance, annuities, retirement products | Insurance (via DFHS) | Distribute carrier products through direct selling agreements | Diversifies revenue beyond securities-market cycles |
4. Competitive Landscape
The 10-K describes the business as operating in "an intensely competitive industry" facing "growing pressure to provide services at lower fees," and names its direct competitive set as small- to mid-size bank holding companies with greater capital and resources, along with other broker-dealers, asset managers, and boutique firms.
- Large national/regional players — Raymond James, Stifel, Piper Sandler, Jefferies: far larger balance sheets, broader research and underwriting shelves, and established HNW advisor networks; Dominari is a small challenger by comparison.
- Boutique investment banks: Dominari's advisory/ECM business competes directly with boutique shops on deal-by-deal mandates, where relationships and speed matter more than scale.
- Independent RIAs/wealth managers: compete for the same HNW client assets Dominari's wealth-management unit targets.
- Management's stated differentiators are client insight, retaining skilled professionals, breadth of services, and an "entrepreneurial culture" — soft advantages rather than structural cost or scale edges.
5. Strategic Strengths & Risks
Strengths
- Holds the hard-to-replicate regulatory licenses (FINRA broker-dealer, SEC-registered investment adviser, NY insurance license) needed to operate across brokerage, advisory, and insurance lines.
- Advisor/client relationships inherited from Fieldpoint Private give it an existing HNW book rather than a cold start.
- High-profile advisory-board visibility (Donald Trump Jr. and Eric Trump hold personal equity stakes and advisory roles) has brought outsized brand awareness and capital-markets access for a firm of its size.
- Recently monetized a non-core asset — selling 23,199,205 shares of ABTC common stock for $32.4 million (closed January 20, 2026) — strengthening the balance sheet and funding a special dividend.
Risks
- Small scale: only 36 full-time employees; it competes against firms with vastly greater capital and distribution.
- Revenue concentration in capital-markets-sensitive fees (IB deal fees, trading) that are cyclical and lumpy.
- Dilution/capital-raise risk: the company has repeatedly tapped equity markets (e.g., a $13.5 million registered direct offering) to fund growth, which dilutes existing shareholders.
- Regulatory/net-capital constraints: the broker-dealer subsidiary's minimum regulatory capital rules can limit cash available to the parent, including for dividends.
- Key-person and headline risk: significant investor attention tied to the Trump-family association introduces reputational and political-news-cycle volatility unrelated to core operating performance.
6. Financial Overview
| Metric | Figure | Context |
|---|---|---|
| Full-time employees (as of 12/31/2025) | 36 | Confirms genuinely small-cap operating footprint |
| Fieldpoint Private Securities acquisition cost | $2.0M (20%, Oct. 2022) + $1.4M (80%, Mar. 2023) = $3.4M total | Founding transaction for Dominari Securities LLC |
| ABTC common stock sale | 23,199,205 shares sold for $32.4 million (closed Jan. 20, 2026) | Non-core asset monetization, bolsters cash/balance sheet |
| Special cash dividend | $0.432 per share (declared Dec. 11, 2025; paid Jan. 26, 2026) | Signals the ABTC proceeds were partly returned to shareholders |
| Registered direct offering | ~$13.5 million | Recent equity capital raise to fund operations/growth |
| Equity Incentive Plan increase | +10,000,000 shares (approved Mar. 4, 2026) | Expands equity compensation capacity, a dilution watch item |
Note: the specific 10-K excerpt reviewed did not surface consolidated revenue, total assets, or net income figures; the table above reflects the concrete financial events the filing and subsequent disclosures actually state.
7. Summary Conclusion
Dominari Holdings is a small financial-services holding company that re-platformed itself from a legacy biotech shell (Spherix/AIkido Pharma) into a licensed wealth-management, investment-banking, and insurance business centered on Dominari Securities LLC. Its model is straightforward fee-and-commission intermediation on client assets and deal flow, supplemented by alternative-investment SPVs and an insurance joint venture, but it remains tiny relative to the regional and boutique firms it competes against.
The company's near-term story is less about organic scale than about balance-sheet opportunism — monetizing a large ABTC stock position, raising equity capital, and returning cash via a special dividend — layered on top of unusually high public visibility from its Trump-family advisory-board ties. That visibility is a double-edged asset: it has aided capital access and brand recognition, but it is not a structural competitive moat, and the underlying business still faces the scale, concentration, and regulatory-capital constraints typical of a small broker-dealer holding company.